The OncoRat provides unique advantages over mouse models for conducting in vivo efficacy evaluation of potential cancer therapies. Better engraftment rates in the OncoRat result in a wider variety of tumor biology. Other advantages include larger tumor, blood and tissue samples for biomarker and downstream analysis as well as a better model for ADME, PK/PD and toxicology.
Hera can consult with your team to select the most appropriate tumor model. Your molecule can be profiled in a variety of tumor models and compared or combined to standards of care for combination studies and IND filing.
If your model of interest is not listed below it can be established in the OncoRat. Model establishment is typically much faster than in mouse, in particular for PDX models due to the larger tumor growth.